Eric Scofield, MD
Hematology & Oncology · Wilmington, NCNPI 1295017465
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Pfizer accounts for 64.6% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2024 at $5,351 and has fallen 82.0% since, to $962 in 2025.
Across 121 payments — averaging $60.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$5K
- AstraZeneca$394
- Johnson & Johnson$201
- Amgen$200
- Merck$166
- Astellas Pharma US Inc$164
- plus $1K from 31 others
What the payments were for
- Speaking & faculty fees$4,10456%
- Travel & lodging$2774%
- Food & beverage$2,58935%
- Education$3505%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 12 | $4,730 |
| AstraZeneca(2 entities) | 15 | $394 |
| Johnson & Johnson(2 entities) | 10 | $201 |
| Amgen | 2 | $200 |
| Merck | 7 | $166 |
| Astellas Pharma US Inc | 3 | $164 |
| Bristol Myers Squibb | 9 | $152 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $113 |
| AbbVie | 5 | $106 |
| Novartis | 4 | $98 |
| Daiichi Sankyo Inc. | 4 | $86 |
| Eisai Inc. | 5 | $84 |
| Tersera Therapeutics LLC | 5 | $83 |
| E.r. Squibb & Sons, L.L.C. | 2 | $81 |
| Genentech USA, Inc. | 3 | $67 |
| Beone Medicines USA, Inc. | 3 | $66 |
| EMD Serono, Inc. | 3 | $49 |
| Beigene USA, Inc. | 2 | $46 |
| Geron Corporation | 2 | $39 |
| Foundation Medicine, Inc. | 2 | $38 |
| Exelixis Inc. | 2 | $37 |
| Mirati Therapeutics, Inc. | 2 | $31 |
| Taiho Oncology, Inc. | 1 | $24 |
| Fennec Pharmaceuticals, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| GSK | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $21 |
| Incyte Corporation | 1 | $20 |
| Array Biopharma Inc | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Gilead | 1 | $17 |
| Masimo Corporation | 1 | $17 |
| Bayer | 1 | $17 |
| Cardinal Health 414 LLC | 1 | $17 |
| Servier Pharmaceuticals LLC | 1 | $16 |
| ADC Therapeutics America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,320 in reported general payments places this provider in the 70th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 88 | $1,082,400 |
| CabometyxCabozantinib S-Malate | 22 | $507,173 |
| Abiraterone Acetate | 526 | $366,823 |
| TepmetkoTepotinib Hcl | 12 | $271,098 |
| LenvimaLenvatinib Mesylate | 11 | $261,516 |
| BrukinsaZanubrutinib | 17 | $246,635 |
| XtandiEnzalutamide | 24 | $221,754 |
| LynparzaOlaparib | 11 | $181,714 |
| ErleadaApalutamide | 12 | $179,239 |
| CalquenceAcalabrutinib Maleate | 12 | $160,918 |
| OrgovyxRelugolix | 53 | $136,294 |
| Lenalidomide | 13 | $133,994 |
| EliquisApixaban | 96 | $81,322 |
| XareltoRivaroxaban | 55 | $72,871 |
| Imatinib Mesylate | 16 | $65,951 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $17 | $1,082,40088 claims |
| Exelixis Inc.Cabometyx | $37 | $507,17322 claims |
| AstraZenecaLynparza, Calquence | $394 | $342,63123 claims |
| EMD Serono, Inc.Tepmetko | $49 | $271,09812 claims |
| Eisai Inc.Lenvima | $84 | $261,51611 claims |
| Johnson & JohnsonErleada, Xarelto | $201 | $252,10967 claims |
| Beigene USA, Inc.Brukinsa | $46 | $246,63517 claims |
| Astellas Pharma US IncXtandi | $164 | $221,75424 claims |
| PfizerEliquis | $4,730 | $81,32296 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Wilmington
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
- Shelbi AtrashCharlotte$994K
- Phillip FebboDurham$749K
- Angela AlistarWinston Salem$509K
- Ravi PaluriWinston Salem$314K
- Matthew McKinneyDurham$277K
- Jared WeissChapel Hill$217K
- Joshua ZeidnerChapel Hill$208K
- Taewoong ChoiDurham$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.